{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(13)"],"submitter":["Patel AA"],"pubmed_abstract":["<h4>Abstract</h4>Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these therapies have been incorporated into the management of accelerated/blast-phase MPNs (MPN-AP/BP). We performed a multicenter analysis to investigate outcomes of patients diagnosed with MPN-AP/BP in 2017 or later. In total, 202 patients were identified; median overall survival (OS) was 0.86 years. We also analyzed patients based on first-line treatment; the 3 most common approaches were intensive chemotherapy (n = 65), DNA methyltransferase inhibitor (DNMTi)-based regimens (n = 65), and DNMTi + venetoclax-based regimens (n = 54). Median OS was not signi"],"journal":["Blood advances"],"pagination":["3468-3477"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11260843"],"repository":["biostudies-literature"],"pubmed_title":["Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era."],"pmcid":["PMC11260843"],"pubmed_authors":["Davidson MB","Dean R","Muthiah C","Bradley T","Odenike O","Oh TS","Burkart M","Cursio JF","Patel AA","Guru Murthy GS","Abaza Y","Gupta V","Viswabandya A","Madero-Marroquin R","Yoon JJ","Kassner J","Chen EC","Rampal RK","Johnston H","Garcia JS","Shallis RM","Iyer SG","Madarang E","Gross I","Pettit KM"],"additional_accession":[]},"is_claimable":false,"name":"Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.","description":"<h4>Abstract</h4>Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these therapies have been incorporated into the management of accelerated/blast-phase MPNs (MPN-AP/BP). We performed a multicenter analysis to investigate outcomes of patients diagnosed with MPN-AP/BP in 2017 or later. In total, 202 patients were identified; median overall survival (OS) was 0.86 years. We also analyzed patients based on first-line treatment; the 3 most common approaches were intensive chemotherapy (n = 65), DNA methyltransferase inhibitor (DNMTi)-based regimens (n = 65), and DNMTi + venetoclax-based regimens (n = 54). Median OS was not signi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-05-18T13:25:48.439Z","creation":"2025-05-18T13:25:48.439Z"},"accession":"S-EPMC11260843","cross_references":{"pubmed":["38739724"],"doi":["10.1182/bloodadvances.2024012880"]}}